Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT HFA versus PENECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT HFA versus PENECORT.
FLOVENT HFA vs PENECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a synthetic corticosteroid that binds to glucocorticoid receptors, increasing the synthesis of lipocortins, which inhibit phospholipase A2, thereby reducing arachidonic acid release and decreasing prostaglandin and leukotriene production. It also suppresses inflammatory cell migration and cytokine release, leading to reduced airway inflammation and hyperreactivity.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
Adult: 88-880 mcg twice daily via oral inhalation; typical starting dose: 88 mcg twice daily for patients previously on bronchodilators alone, 220 mcg twice daily for patients on inhaled corticosteroids.
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 7.8 hours (range 6.5-10.6 hours) after inhalation, supporting twice-daily dosing.
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
Primarily fecal (approximately 60-80%) after biliary elimination, with renal excretion accounting for <5% as unchanged drug and metabolites.
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid